BMY - Bristol-Myers Squibb Company
56.89 +0.01 (0.01%)
After hours: 5:19PM EDT
| Previous Close | 56.63 |
| Open | 56.58 |
| Bid | 56.42 x 1400 |
| Ask | 57.17 x 800 |
| Day's Range | 56.29 - 56.91 |
| 52 Week Range | 49.96 - 70.05 |
| Volume | 3,730,368 |
| Avg. Volume | 7,801,515 |
| Market Cap | 92.973B |
| Beta | 1.11 |
| PE Ratio (TTM) | 101.39 |
| EPS (TTM) | 0.56 |
| Earnings Date | Jul 26, 2018 |
| Forward Dividend & Yield | 1.60 (2.83%) |
| Ex-Dividend Date | 2018-07-05 |
| 1y Target Est | 57.56 |
Markit•4 days agoSee what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BMY. Over the last one-month, outflows of investor capital in ETFs holding BMY totaled $1.82 billion.
- Zacks•5 days ago
Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.
- TheStreet.com•6 days ago
3 Pharma Stocks Goldman Sachs Sees as Buys
Stagnant deal activity has investors "losing patience with the large cap pharma sector," according to a note from Goldman Sachs analyst Jami Rubin. Small- and mid-cap biotech companies are being valued at all time highs, and companies are staying away from new acquisitions for fear of paying high premiums for them, Rubin wrote. "Pharma management teams are facing investor pressure to put their capital to work, but balancing the risk of overpaying with the risk of doing nothing has led to low levels of deal activity thus far this year in our view," Rubin said.
- Zacks•6 days ago
Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer
Bristol-Myers' (BMY) Opdivo in combination with its Yervoy received the FDA approval to treat patients with metastatic colorectal cancer (mCRC) that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.
Markit•6 days agoSee what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co NYSE:BMY
- Fortune•7 days ago
Russian Drugmaker Granted License to Produce Celgene Copycat
Russian drugmaker Nativa got a compulsory license to produce a cheaper version of Celgene's Revlimid.
- American City Business Journals•7 days ago
Moffitt licensing deal could provide new approach for some cancer patients
Moffitt Cancer Center and MultiVir Inc., a Houston-based immune oncology company, have agreed to work together to develop a personalized cancer vaccine. The therapeutic vaccine, made up of a patient’s own cells, would activate cancer-fighting immune cells to target a genetic mutation found in nearly 50 percent of all cancers, Moffitt said in a press release. Moffitt, based in Tampa and the only Florida institution designated by the National Cancer Institute as a comprehensive cancer center, is a leader in the life sciences industry that economic developers hope to expand in the Tampa Bay area, because of the high-skill, high-wage jobs in the sector.
- Business Wire•7 days ago
Bristol-Myers Squibb’s Opdivo® (nivolumab) + Low-Dose Yervoy® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and...
Bristol-Myers Squibb’s Opdivo® + Low-Dose Yervoy® is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following T
- American City Business Journals•9 days ago
Could P&G bid for Bristol-Myers Squibb unit?
Bristol-Myers Squibb is considering the sale of its French consumer health care division, and Procter & Gamble CEO David Taylor is in acquisition mode.
- CNW Group•9 days ago
Only Immuno-Oncology Combination Therapy Approved by Health Canada as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
Only Immuno-Oncology Combination Therapy Approved by Health Canada as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
- ACCESSWIRE•9 days ago
Wired News - The European Commission Approves Expanded Indication for Bristol-Myers Squibb's Sprycel
LONDON, UK / ACCESSWIRE / July 9, 2018 / If you want access to our free research report on Bristol-Myers Squibb Co. (NYSE: BMY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BMY as the Company's latest news hit the wire. On July 05, 2018, the Company announced that the European Commission (EC) has approved the indication for Sprycel (dasatinib) to treat children and adolescents aged 1 year to 18 years with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP), and to include a powder for oral suspension formulation.
- Benzinga•10 days ago
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Biotech stocks held their ground in a holiday-shortened week amid a drought of market-moving catalysts. Looking ahead, the following are catalytic events for biotech investors to watch. Conferences Fourth ...
- Zacks•12 days ago
Bristol-Myers' Sprycel Gets EC Approval for Label Expansion
Bristol-Myers (BMY) receives EC approval for the label expansion of Sprycel for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in patients aged one to 18 years.
- Investopedia•13 days ago
Pfizer's Stock Ready for a 10% Rebound
Pfizer Inc. ( PFE) shares have dramatically underperformed during the past three years, rising 9.4% compared to the S&P 500's rise of nearly 31%. Options traders are also betting the stock will gain in the next few months. Pfizer has not only underperformed the broader stock market, but its valuation is among the cheapest of some of the other big pharmaceuticals.
InvestorPlace•13 days agoGo Long Pfizer Stock — It’s an Easy Pill to Swallow
Pfizer (NYSE:PFE) is a pharma/biotech dinosaur. This stock is a survivor of decades of stock market turmoils and corrections. It currently sits on a potential long-term technical breakout point on the monthly chart.
- Business Wire•13 days ago
European Commission Approves Expanded Indication for Sprycel (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Approval includes the first powder for oral suspension formulation of a tyrosine kinase inhibitor developed for administration in pediatric patients
- Motley Fool•16 days ago
The 5 Biggest Blockbuster Drugs of 2024, and the Companies Poised to Profit From Them
Find out which drugs -- and which drugmakers -- could be the greatest winners six years from now.
- Business Wire•19 days ago
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended expanded approval of the current indications for Opdivo to include the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.
- Investopedia•22 days ago
Bristol-Myers Stock May Rebound 9% Short Term
Bristol-Myers Squibb Co.'s ( BMY) stock is down over 20% from its highs in 2018, but the stock is poised to recoup some of those losses, based on technical analysis, by about 9%. Bristol dropped in mid-April after reporting positive data from a phase 3 trial of its cancer drug Optivo. The stock appears to have put in a solid technical bottom around $50.50 and have been trending higher along a new technical uptrend.
- Market Realist•22 days ago
How Pfizer’s Valuation Compares
Biopharmaceutical giant Pfizer’s (PFE) portfolio includes medicines, vaccines, and consumer healthcare products. In Q1 2018, Pfizer’s top line rose ~1% YoY (year-over-year) to $12.9 billion. The chart below shows its EPS and revenue since Q1 2017, and estimates for Q2 2018.
Markit•22 days agoSee what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co NYSE:BMY
- ACCESSWIRE•22 days ago
Wired News - FDA Accepts Bristol-Myers Squibb’s Application for Opdivo Plus Low-Dose Yervoy for First-Line Non-Small Cell Lung Cancer Treatment
LONDON, UK / ACCESSWIRE / June 26, 2018 / If you want access to our free research report on Bristol-Myers Squibb Co. (NYSE: BMY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BMY as the Company's latest news hit the wire. On June 22, 2018, the Company announced that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with low-dose Yervoy (ipilimumab) for the treatment of first-line advanced non-small cell lung cancer (NSCLC) in patients with tumor mutational burden (TMB) ≥10 mutations per megabase (mut/Mb).
- Morningstar•23 days ago
13 Companies With Attractive, Low-Risk Dividends
New Morningstar research shows that our metrics can improve investors' success when it comes to finding high-quality companies with safe dividends. "A company with a [economic] moat around its business is able to sustain its profits and fend off competition. The Morningstar Dividend Yield Focus Index combines these metrics to home in on the highest-yielding stocks of companies that are financially healthy enough to sustain and even grow their dividend.
Markit•23 days agoSee what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co NYSE:BMY
- Zacks•26 days ago
Bristol-Myers' BLA for Opdivo Label Expansion Accepted by FDA
Bristol-Myers Squibb Company (BMY) announces that the FDA accepts its supplemental Biologics License Application (sBLA) for the label expansion of its blockbuster immuno-oncology drug Opdivo.
